Samples

Revenue segments as reported by the company.

Test revenue

Other revenue

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Change in fair value of contingent consideration

Asset impairment

Restructuring

Gain on sale of RUO kit assets

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Invitae

Invitae Corp. engages in the provision of genetic information into mainstream medical practice. It includes comprehensive panels for hereditary conditions in cancer, cardiology, neurology, pediatric, and rare diseases. The company was founded by Randal W. Scott and Sean E. George on January 13, 2010 and is headquartered in San Francisco, CA.

Earnings data Q1 2020

Earnings data Q2 2020

Earnings data Q3 2020

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q1 2024

Invitae reports strong Q4 earnings, eyes growth amid challenges

Invitae's Q4 2022 performance showcased revenue growth, improved margins, and reduced cash burn, positioning the company for sustainable growth.
Strategic investments in key growth areas and a focus on customer experience and profitability underpin Invitae's vision for the future.
Addressing supply chain challenges while seizing opportunities for expansion and innovation will be critical for Invitae's continued success.

Invitae (NVTA) reports robust Q1 earnings and advances in PCM technology

Invitae's Q1 2023 earnings call highlighted strong financial performance, operational strengths, and strategic advancements in PCM technology.
The company's focus on growth, margin expansion, and debt management underscores a path towards sustainable profitability.
While facing challenges in reimbursement dynamics and competitive landscape, Invitae remains poised to capitalize on growth opportunities.

Invitae reports Q2 revenue growth, adjusts guidance amid challenges

Invitae shows progress towards profitability with improved margins and reduced cash burn.
Challenges in hereditary cancer revenue and PGX exit impact revenue guidance.
Focus on expanding customer base, improving reimbursement, and reducing cash burn.
Continuous investment in products for future growth and competitiveness.

Invitae reports robust Q3 earnings, addresses financial concerns proactively

Invitae's Q3 2023 performance was strong, with revenue growth and margin expansion. The company faces challenges in capital structure and insurance payments but is actively addressing them. Opportunities lie in revenue growth, operational improvements, and expanding genetic testing services.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Invitae is a genetic information company whose mission is to bring genetic information into routine medical practice to improve the quality of healthcare for billions of people.  Specializing in genetic diagnostics for hereditary disorders, Invitae is aggregating the world’s genetic tests into a single service with better quality, faster turnaround time, and a lower price than most single-gene diagnostic tests today.  What’s our plan? It takes three steps:  --Make genetic testing more affordable and accessible than ever before. --Build a secure and trusted genome management infrastructure. --Design a new global community for sharing genetic information to advance science and medicine.  Today, we are reinventing genetic testing by lowering the barriers for clinicians and patients to obtain diagnostic genetic information. Together we can improve healthcare for billions of people.

Invitae announced an agreement to exchange old notes for new notes plus more than 15.8 million new shares. Website StockNews.com also downgraded the stock from hold to sell.

Why Invitae Stock Is Crashing Today

– Research published in European Urology Oncology shows restrictive genetic testing criteria miss a significant number of prostate cancer patients with potentially actionable inherited variants – – Offering germline testing to all prostate cancer patients could improve access to critical genetic information, particularly for historically underrepresented groups – SAN FRANCISCO , Aug. 15, 2023 /PRNewswire/ --  Invitae  (NYSE: NVTA), a leading medical genetics company, today announced findings from its PROCLAIM trial , published in European Urology Oncology , showing that almost half of prostate cancer patients with clinically actionable pathogenic/likely pathogenic germline variants (PGVs) could be missing out on genetics-informed care due to restrictive criteria for genetic testing. In this prospective, observational study, nearly 1,000 men with prostate cancer unselected for family history of cancer, age at diagnosis or stage of disease, underwent germline genetic testing of 84 cancer predisposition genes under the care of urologists across the U.S., primarily  in community clinics.

Clinical Trial Results Support Genetic Testing of All Patients with Prostate Cancer

– Christine Gorjanc resumes role as Chair of the Audit Committee of the Board of Directors for Invitae – SAN FRANCISCO , Aug. 14, 2023 /PRNewswire/ -- Invitae (NYSE: NVTA), a leading medical genetics company, today announced that Robert Dickey has been named its interim chief financial officer (CFO), effective immediately. Christine Gorjanc, who had assumed the interim CFO role in June 2023, will transition back to her prior role as the Company's Chair of the Audit Committee of the Board of Directors and member of the Compensation Committee of the Board of Directors, effective immediately.

Invitae Announces Selection of Finance Executive Robert Dickey as Interim CFO

The innovative medical services company is making adjustments to improve the bottom line.

Down 96%, Is Invitae Stock a Buy?

Invitae Corporation (NYSE:NVTA ) Q2 2023 Earnings Call Transcript August 8, 2023 4:30 PM ET Company Participants Hoki Luk - VP, IR and Corporate Development Ken Knight - President and CEO Conference Call Participants Dan Brennan - Cowen Madison Pasterchick - Morgan Stanley Dave Delahunt - Goldman Sachs Rachel Vatnsdal - JP Morgan Puneet Souda - SVB Kyle Crews - Credit Suisse David Westenberg - Piper Sandler Operator Hello, and welcome to the Invitae Second Quarter 2023 Financial Results Conference Call. My name is Alex.

Invitae Corporation (NVTA) Q2 2023 Earnings Call Transcript

Invitae (NVTA) came out with a quarterly loss of $0.30 per share versus the Zacks Consensus Estimate of a loss of $0.37. This compares to loss of $0.68 per share a year ago.

Invitae (NVTA) Reports Q2 Loss, Lags Revenue Estimates

– Reported revenue of $120.5 million, a 12% year-over-year decrease due to exited businesses and geographies; pro forma revenue up slightly year-over-year –  – GAAP gross margin was 27.4% and non-GAAP gross margin was 49.8%; continued improvement in non-GAAP gross margin for eight consecutive quarters – – Company improves ongoing cash burn annual guidance to $220-$245 million; adjusts 2023 revenue guidance to $480-$500 million from over $500 million previously – – Conference call and webcast today at 4:30 p.m. Eastern Time / 1:30 p.m.

Invitae Reports Second Quarter 2023 Financial Results

Akari Therapeutics

Ardelyx

Carmell Therapeutics Corp

Homology Medicines

Rigetti Computing

Penny stocks hold a distinctive charm for many investors. Amidst fluctuating market trends and the occasional downturn, there's often a group of these low-cost stocks surging in value.

Best Penny Stocks To Buy? 6 To Watch Before Next Week

Nano Dimension

Nano Dimension and Invitae are two of the most innovative companies in the world.

Best Beaten-Down Growth Stock to Buy: Nano Dimension vs. Invitae

SAN FRANCISCO , July 26, 2023 /PRNewswire/ --  Invitae (NYSE: NVTA), a leading medical genetics company, today announced that it will report its second quarter 2023 financial results on Tuesday, August 8, 2023, and will host a conference call and webcast that day at 4:30 p.m. Eastern / 1:30 p.m.

Invitae to Announce Second Quarter 2023 Financial Results on Tuesday, August 8, 2023

Stock market analysts have conflicting opinions about the market value of this genetic testing business. Worth more than $10 billion at its peak, beaten-down Invitae could provide huge returns if it can regain a fraction of its former market cap.

Down 97%, Is It Finally Time to Buy Invitae Stock?

Invitae (NVTA) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Invitae (NVTA) Upgraded to Buy: Here's Why

Popular investment manager Cathie Wood is known for investing in innovative growth stocks.

Down 98% Is This Cathie Wood Stock a Screaming Buy?

Emergent BioSolutions

Emergent BioSolutions just got a nod from regulators for over-the-counter use of a product to fight opioid overdose. Invitae is making progress on a plan to reach positive cash flow.

Better Recovery-Story Buy: Emergent BioSolutions or Invitae?

Invitae Corporation (NYSE:NVTA ) Annual William Blair Growth Stock Conference Call June 7, 2023 1:40 PM ET Company Participants Ken Knight - President and Chief Executive Officer Hoki Luk - Investor Relations Conference Call Participants Andrew Brackmann - William Blair Andrew Brackmann Hi, everyone. Good afternoon.

Invitae Corporation (NVTA) Annual William Blair Growth Stock Conference Call

Editas Medicine

CRISPR Therapeutics

An upcoming event has gene editing stocks rising today. Editas Medicine (NASDAQ: EDIT ) has announced plans to present some important trial data via a live webinar next week on June 12 at 8 a.m.

Why Are Gene Editing Stocks EDIT, NVTA, CRSP Up Today?

Intellia Therapeutics

Intellia is advancing gene-editing candidates for diseases with limited treatment options. Invitae is making progress on a plan to speed up the timeline to positive cash flow.

Wall Street Says These 2 Stocks May Double. Should You Buy Them?

SAN FRANCISCO , May 31, 2023 /PRNewswire/ -- Invitae (NYSE: NVTA), a leading medical genetics company, today announced that Ken Knight, president and chief executive officer, will present at the William Blair 43rd Annual Growth Stock Conference on Wednesday, June 7, 2023, at 12:40 p.m. Central Time.

Invitae to Present at the William Blair 43rd Annual Growth Stock Conference

– Study findings confirm the importance of improving education among clinicians and streamlining processes to increase adoption of testing in routine cancer care – SAN FRANCISCO , May 26, 2023 /PRNewswire/ --  Invitae  (NYSE: NVTA), a leading medical genetics company, today announced nine studies to be presented at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting held in Chicago from June 2-6, 2023. The new research insights highlight innovations in genetic testing in a variety of clinical settings, population groups and cancer types, and reinforce the need to reduce barriers to genetic services to help patients receive the most effective care and monitoring.

New Research Insights to be Presented by Invitae at the 2023 ASCO Annual Meeting Reinforce the Critical Role of Germline Genetic Testing in Oncology

SAN FRANCISCO , May 25, 2023 /PRNewswire/ -- Invitae (NYSE: NVTA), a leading medical genetics company, today announced that Chief Financial Officer (CFO) Yafei (Roxi) Wen is resigning to pursue other opportunities, effective June 30, 2023. The Company has initiated a search for a new CFO.

Invitae Announces CFO Transition and Selection of Veteran Finance Executive Christine Gorjanc as Interim CFO

SAN FRANCISCO , May 15, 2023 /PRNewswire/ -- Invitae  (NYSE: NVTA), a leading medical genetics company, today announced that it intends to appeal the verdict delivered by a jury at the United States District Court for the District of Delaware. The jury found that Invitae's products using Anchored Multiplex PCR ("AMP") chemistry infringe certain Natera, Inc. patents.

Invitae to Appeal Trial Verdict

Invitae (NVTA) came out with a quarterly loss of $0.37 per share versus the Zacks Consensus Estimate of a loss of $0.41. This compares to loss of $0.78 per share a year ago.

Invitae (NVTA) Reports Q1 Loss, Tops Revenue Estimates

Invitae Corporation (NYSE:NVTA ) Q1 2023 Earnings Conference Call May 9, 2023 4:30 PM ET Company Participants Hoki Luk - Investor Relations Ken Knight - President & Chief Executive Officer Robert Daber - Chief Scientific Officer Roxi Wen - Chief Financial Officer Conference Call Participants Matthew Sykes - Goldman Sachs Operator Hello, everyone, and welcome to the Invitae First Quarter 2023 Financial Results Conference Call. My name is Emily, and I will be your conference coordinator today.

Invitae Corporation (NVTA) Q1 2023 Earnings Call Transcript

– Reported revenue of $117.4 million, a 5% year-over-year decrease due to exited businesses and geographies; pro forma year-over-year revenue growth was ~10% –  – Continued improvement in gross margin and ongoing cash burn trends – – Company reiterates key 2023 financial guidance metrics – – Conference call and webcast today at 4:30 p.m. Eastern Time / 1:30 p.m.

Invitae Reports First Quarter 2023 Financial Results

Ginkgo Bioworks Holdings

Grab Holdings Ltd

Trevena

Are these the best penny stocks to buy right now? Here's what's moving on Monday.

News for Invitae Stock (NVTA)